Variability in Immunohistochemical Detection of Programmed Death Ligand 1 (PD-L1) in Cancer Tissue Types

Int J Mol Sci. 2016 May 21;17(5):790. doi: 10.3390/ijms17050790.

Abstract

In normal cell physiology, programmed death 1 (PD-1) and its ligand, PD-L1, play an immunoregulatory role in T-cell activation, tolerance, and immune-mediated tissue damage. The PD-1/PD-L1 pathway also plays a critical role in immune escape of tumor cells and has been demonstrated to correlate with a poor prognosis of patients with several types of cancer. However, recent reports have revealed that the immunohistochemical (IHC) expression of the PD-L1 in tumor cells is not uniform for the use of different antibodies clones, with variable specificity, often doubtful topographical localization, and with a score not uniquely defined. The purpose of this study was to analyze the IHC expression of PD-L1 on a large series of several human tumors to correctly define its staining in different tumor tissues.

Keywords: PD-L1; immunohistochemical staining; tissue type’s variability.

MeSH terms

  • B7-H1 Antigen / metabolism*
  • Humans
  • Immunohistochemistry / methods
  • Immunohistochemistry / standards*
  • Neoplasms / diagnosis*
  • Neoplasms / metabolism
  • Organ Specificity
  • Sensitivity and Specificity

Substances

  • B7-H1 Antigen
  • CD274 protein, human